Honest Health and Albany Med Health System Partner to Advance Value-Based Care in Northeastern New York
Collaboration will enhance physician support, drive innovation, and improve patient outcomes
NASHVILLE, Tenn. and ALBANY, N.Y. , April 30, 2025 /PRNewswire/ -- Albany Med Health System, the largest and only regionally governed not-for-profit health system in northeastern New York and western New England, has announced a new partnership with Honest Health, a physician-led, value-based care enablement organization. This collaboration, which further extends Honest Health's already established partnerships from Western New York to the Capital Region, will equip providers with the necessary tools, data, and support to enhance the patient experience, improve outcomes, and drive efficiencies resulting in lower costs.
Through its proven expertise in value-based care, Honest Health will empower the Albany Med Health System's physicians, advanced practice providers, and nurses with real-time insights, predictive analytics, and population health management strategies. This approach enables clinicians to focus their time and energy where it matters most - delivering proactive, high-quality care, rather than navigating outdated, volume-driven payment models.
'The Albany Med Health System is committed to delivering the highest quality of care to the communities we serve,' said Dennis P. McKenna, MD, president and CEO of the Albany Med Health System. 'Through our partnership with Honest Health, we are ensuring our providers have access to innovative solutions that enhance patient outcomes, improve operational efficiency, and create a more sustainable future for health care in our region.'
With initial focus on traditional Medicare, a key aspect of this partnership includes a shared commitment to clinical and financial accountability, ensuring that both organizations are aligned in delivering measurable improvements in care. By leveraging advanced technology, streamlined processes, and a collaborative approach, Honest and Albany Med Health System will build a comprehensive partnership that prioritizes value-based care.
'At Honest Health, we believe that true transformation in healthcare happens when physicians have the right tools and resources to focus on value over volume,' said Robert Bessler, MD, chief executive officer of Honest. 'Partnering with Albany Med Health System represents a shared commitment to building a sustainable, patient-first model of care that improves quality, enhances efficiency, and supports providers every step of the way.'
About Albany Med Health System
Comprised of Albany Medical Center, Albany Medical College, Columbia Memorial Health, Glens Falls Hospital, Saratoga Hospital, and the Visiting Nurses, the Albany Med Health System is the largest locally governed, not-for-profit health system serving northeastern New York and western New England. The System is the region's largest private employer, and each member institution carries a century-long tradition caring for our communities. The Albany Med Health System has 1,520 hospital beds, more than 800 physicians, 125 outpatient locations, a children's hospital, and research enterprise serving the three million people of our region.
About Honest Health
Honest Health is a physician-led, value-based care enablement organization that partners with health systems and providers to drive improved patient outcomes while reducing costs. Honest supports clinicians by offering actionable insights, operational expertise, and shared accountability in care models that prioritize quality and value. For more information, visit honesthealth.com
CONTACT: Debbie McKee, 315-857-4541
View original content to download multimedia: https://www.prnewswire.com/news-releases/honest-health-and-albany-med-health-system-partner-to-advance-value-based-care-in-northeastern-new-york-302442551.html
SOURCE Honest Health
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Intercept
3 hours ago
- The Intercept
Trump Puts Lives at Risk by Revoking Emergency Abortion Guidelines for Hospitals
The Trump administration rescinded Biden-era guidance that explicitly required emergency rooms to provide abortions to pregnant patients if such care would save their lives. Medical experts expect the policy shift to sow chaos in hospitals and endanger pregnant people throughout the U.S. In the aftermath of the Supreme Court's move to overturn Roe v. Wade, the Biden administration issued guidance related to the Emergency Medical Treatment and Active Labor Act, or EMTALA, a federal law that requires health care providers that take Medicare to provide 'stabilizing' medical treatment to all patients experiencing medical emergencies. In a 2022 letter to health care providers, Health and Human Services Secretary Xavier Beccerra wrote that if a doctor believes a pregnant patient at an emergency room 'is experiencing an emergency medical condition as defined by EMTALA, and that abortion is the stabilizing treatment necessary to resolve that condition, the physician must provide that treatment.' The memo also clarified that EMTALA preempts state law in cases where abortion is illegal with exceptions narrower than those in EMTALA. In a press release Tuesday, the Trump administration rescinded the older guidance, stating that the previous rules 'do not reflect the policy of this Administration.' The release noted that Centers for Medicare and Medicaid Services 'will work to rectify any perceived legal confusion and instability created by the former administration's actions.' 'In places where doctors and hospitals are being threatened with both criminal and civil penalties for providing abortion care, it will cause a delay.' Abortion providers and experts in reproductive health argue that the vagueness of the new guidance will create uncertainty in emergency rooms, denying pregnant people equal access to care and putting lives at risk in states that have restricted or banned abortion. 'The Trump Administration would rather women die in emergency rooms than receive life-saving abortions,' said Nancy Northup, President and CEO at the Center for Reproductive Rights. 'In pulling back guidance, this administration is feeding the fear and confusion that already exists at hospitals in every state where abortion is banned. Hospitals need more guidance right now, not less.' The Trump administration told The Intercept that the idea that the new guidance puts lives at risk is 'false.' 'CMS will continue to enforce EMTALA, which protects all individuals who present to a hospital emergency department seeking examination or treatment, including for identified emergency medical conditions that place the health of a pregnant woman or her unborn child in serious jeopardy,' Department of Health and Human Services spokesperson Andrew Nixon wrote in a statement to The Intercept. Even before the Trump administration rescinded the Biden-era guidance, dozens of pregnant women reported being turned away for emergency medical care since the fall of Roe. A ProPublica report found that at least five women have died as a result of abortion bans since Roe v. Wade was overturned. Most reproductive health care experts believe the number is far higher than what's been reported. 'We already know that women have died because physicians didn't act because of fear surrounding what they or couldn't do under certain state bans,' said Dana Sussman, senior vice president at Pregnancy Justice, a non-profit reproductive justice organization. 'We know that women have died because they have been scared to get care, because they self managed abortions. We know that more women will die, and we and there are probably women who have died, and we will never know their names.' Sussman said that the new guidance will only make it harder for hospitals to feel comfortable providing lifesaving care to pregnant people. 'I think inevitably it will create many more challenges when it comes to what hospitals are advising their physicians, what physicians feel comfortable doing in different states and and I do think that it's putting more lives,' she said. Last year, the Supreme Court heard oral arguments in a case brought by the Biden Administration challenging Idaho's abortion ban on the grounds that it violated EMTALA by prohibiting abortion care in too many circumstances. The court ultimately punted — refusing to add clarity — but allowing emergency abortions to go forward in the state. The Trump Department of Justice declined to continue prosecuting the Idaho case, an early signal that it planned to rescind the Biden guidance. Jamilla Perritt, an OB-GYN and abortion provider in Washington who is also president of the nonprofit Physicians for Reproductive Health, said it's important to clarify that EMTALA still stands, even if the administration has tried to muddy the waters. 'This does not change [providers] legal obligation to provide life saving care for people when they report to emergency rooms,' Perritt said. 'The other thing is that it does not change their moral and ethical obligation to do so.' The confusion caused by this announcement, however, will carry risks, argued Perritt. 'In places where doctors and hospitals are being threatened with both criminal and civil penalties for providing abortion care,' she said. 'It will cause a delay. It will give them pause.' It's striking, Perrit said, to see such policy come from an administration that has been masquerading as supportive of families. 'The federal government gets to decide who lives and who dies during pregnancy complications, during emergency events,' she said. 'The hypocrisy is really glaring, because this is the exact same government that's claiming to support children and families that want people to have more babies, but instead it is dismantling the system that protects the lives of pregnant people and their families.'
Health Line
5 hours ago
- Health Line
Does Medicare Cover BCG Treatment for Bladder Cancer?
BCG is an immunotherapy treatment. Medicare may cover BCG when medically necessary to treat certain types of bladder cancer or after a transurethral resection of bladder tumor (TURBT). Bacillus Calmette-Guerin (BCG) is the standard immunotherapy drug for bladder cancer. Immunotherapy uses your own immune system to attack cancer cells. With BCG, the doctor inserts a catheter into your bladder to deposit a drug made from a weakened strain of Mycobacterium bovis, a vaccine for tuberculosis. Original Medicare (parts A and B) covers approved treatments and services for bladder cancer that your healthcare team deems medically necessary, which can include BCG. Read on to learn about when Medicare might cover BCG, your eligibility for coverage, and your anticipated costs. Are you eligible for BCG treatment for bladder cancer with Medicare? Doctors tend to recommend BCG treatment for carcinoma in situ and non-muscle invasive bladder cancer, which includes noninvasive (stage 0) and minimally invasive (stage 1) bladder cancers. They also typically would suggest it after you've received a procedure known as transurethral resection of bladder tumor (TURBT) to reduce your chance of the cancer returning. Generally, Original Medicare should approve BCG if you need it under these circumstances. Part A will cover it while you're hospitalized, whereas Part B will cover it if you get the treatment as an outpatient. If you're enrolled in Medicare Advantage (Part C), you should receive the same coverage. Is Anktiva covered by Medicare? The U.S. Food and Drug Administration (FDA) has approved the drug Anktiva for use alongside BCG treatment. Like BCG, Anktiva is administered into the bladder. Medicare Part A and B may cover Anktiva if medically necessary, with covered BCG treatment. Note that Parts A and B should cover the drug itself and not just the catheter administration procedure. This is because you cannot administer the medication to yourself, in which case it would fall under the coverage of Medicare Part D. That said, currently there is a shortage of the BCG drug. For this reason, according to the Centers for Medicare & Medicaid Services (CMS), Medicare may approve your treatment at a dose less than the usual dose of 81 milligrams (mg) or 1 vial per session. How much does BCG treatment for bladder cancer cost? A 2021 study analyzed the administration of BCG therapy within the Veterans Affairs Health System between 2000 and 2015. After one year, the median cost was around $29,459, increasing to $55,267 by two years, and reaching $117,361 at five years. That said, your share of this cost after your Medicare coverage kicks in depends on the part of Medicare responsible for your coverage. Under Part B, after you've met the 2025 deductible of $257, Part B will pay for 80% of any covered treatment or service. You also have to pay a monthly premium, which starts at $185, depending on your income. Under Part A, in most cases, you don't have a premium, though you must meet a $1,676 deductible. Once you do, Part A will cover your treatment fully for the first 60 days of hospitalization. After that, you begin to incur a daily cost that increases over time until you become responsible for the full, remaining cost. If you're covered by Part C, your plan is managed by a private insurer, which means your premium, deductible, and coinsurance depend on your plan. According to the Centers for Medicaid & Medicare (CMS), the average monthly premium for Part C plans is around $17.00 in 2025. In addition, to remain enrolled in a Part C plan, you still have to pay the Part B premium. That said, some Part C may cover your Part B premium. Where can you get help with the cost of BCG treatment for bladder cancer? Several factors affect the cost of treating bladder cancer, including: how aggressive the cancer is the stage at which it was diagnosed the treatment prescribed by your doctor Managing your medical expenses starts with ensuring that your doctor accepts your Original Medicare or Part C plan. If you're enrolled in Original Medicare, you can also consider enrolling in a Medicare supplement plan (Medigap) to help with out-of-pocket costs, such as copayments and deductibles. You can choose from 10 different plans, depending on factors like your location and coverage needs. However, you cannot use Medigap with Medicare Advantage (Part C) plans. You may also wish to check if you qualify for a Medicare Savings Program (MSP) and Extra Help, and if you might dually qualify for Medicare and Medicaid. Outside of Medicare, you may wish to check non-profit financial assistance programs. What other treatments does Medicare cover for bladder cancer? Medicare Part A covers inpatient hospital stays, including cancer treatments and diagnostics you receive as an inpatient. Part A also offers: some coverage for care at home, such as skilled nursing and physical therapy limited coverage for care in a skilled nursing facility after 3 days in the hospital care in a hospice In the case of medically necessary outpatient treatments and services to treat bladder cancer, Medicare Part B covers: visits with your doctor (including oncologists and other specialists) diagnostic testing (lab tests, ultrasound, etc.) many chemotherapy drugs administered through an IV at your doctor's office or a clinic some chemotherapy drugs administered orally outpatient clinic radiation treatments durable medical equipment, such as feeder pumps and wheelchairs Any treatment drugs you can take yourself would fall under Part D coverage. That said, Medicare may not cover every medication. Always confirm coverage and expected costs before receiving treatment. If Medicare doesn't cover the treatment you need, discuss payment plans or other options with your doctor. Takeaway Medicare covers treatment and services for bladder cancer; however, you may still have significant out-of-pocket costs depending on factors like recommended treatment or the stage of your cancer. You can work with your doctor to develop a treatment plan that maximizes your Medicare coverage. If you have additional coverage, such as a Medicare Part D (prescription drug) plan or a Medigap (Medicare supplement) plan, many of your out-of-pocket costs will be covered.
Yahoo
6 hours ago
- Yahoo
Trump administration rolls back guidance specifying that ERs must offer abortion care when necessary
The US Department of Health and Human Services and the Centers for Medicare & Medicaid Services said Tuesday that they were rescinding 2022 federal guidance to health care providers specifying that people should be able to access an abortion in the event of a medical emergency, even if state laws restrict such procedures. The previous guidance from the Biden administration does not 'reflect the policy of this Administration,' according to an announcement of the policy change. CMS added that it will continue to enforce the federal Emergency Medical Treatment and Labor Act, known as EMTALA, and it specified that the policy included 'identified emergency medical conditions that place the health of a pregnant woman or her unborn child in serious jeopardy.' However, it remains unclear exactly what the change will mean for emergency care, particularly in states with highly restrictive abortion laws. EMTALA requires all US hospitals that have received Medicare money — essentially nearly all of them — to screen everyone who comes into their emergency rooms to determine whether the person has an emergency medical condition without regard for their ability to pay for services. The 1986 law also requires hospitals, to the best of their ability, to stabilize anyone who has an emergency medical condition or to transfer them to another facility that has that capacity. The hospitals must also treat these patients 'until the emergency medical condition is resolved or stabilized.' Pregnant people were singled out in 1989, after reports that some hospitals were refusing to care for uninsured women in labor. Congress expanded EMTALA to specify that it included people who were pregnant and having contractions. In 2021, the Biden administration released the Reinforcement of EMTALA Obligation, which says it is a doctor's duty to provide stabilizing treatment that 'preempts any directly conflicting state law or mandated that might otherwise prohibit or prevent such treatment,' although it did not specify whether an abortion had to be provided. In July 2022, weeks after the US Supreme Court overturned Roe v. Wade, the 1973 ruling that gave pregnant people a constitutional right to an abortion, the Biden administration's guidance further clarified that EMTALA included the need to perform stabilization abortion care if it is medically necessary to treat an emergency medical condition. If a state law banned abortion and did not include an exception for the life or health of the pregnant person, that law was preempted by the federal statute. After Roe was overturned, several states passed highly restrictive abortion bans. Thirteen have total abortion bans, according to the Guttmacher Institute, a research and policy organization focused on sexual and reproductive health that supports abortion rights. Twenty-eight states have abortion bans based on gestational duration: seven ban it at or before 18 weeks' gestation, and 21 states ban abortion at some point after 18 weeks. Idaho has one of the more restrictive laws, making it a felony to perform an abortion at any stage of pregnancy unless it was necessary to save the life of a pregnant person. In 2024, the US Supreme Court formally dismissed an appeal over Idaho's strict abortion ban. The decision was interpreted as meaning that pregnant people should be able to access an abortion in a medical emergency under EMTALA, but experts said that in reality, pregnant people were still being denied care. Some doctors even advised pregnant patients to buy life flight insurance in case they had an emergency complication that the doctors could not treat and the patient had to be flown out of state. In March, the Trump administration took a major step in support of states with abortion bans when it dropped a Biden-era lawsuit against Idaho that sought to protect abortion access in medical emergencies. Tuesday's announcement from CMS says the agency will 'work to rectify any perceived legal confusion and instability created by the former administration's actions.' The American College of Obstetricians and Gynecologists, a professional organization that represents the majority of practitioners in the United States, was critical of the move. 'Rescinding guidance clarifying protections for the care of pregnant people experiencing emergencies is a poor decision that will undoubtedly endanger the lives and health of pregnant women, who are already facing difficulties accessing needed abortion care during obstetrical complications,' Molly Meegan, the group's chief legal officer and general counsel, said in an email Tuesday. She said the announcement will 'deepen confusion' about when emergency care is legal and exacerbate 'overwhelming barriers to care' for people across the US. 'Abortion is an essential part of medical care, and EMTALA protections should be afforded to all patients in need of emergency care, including abortion,' Meegan said. The ACLU, Democracy Forward and the National Women's Law Center, organizations that have advocated for pregnant people's right to an abortion, were also critical of the new decision, characterizing it as 'caving to its anti-abortion allies' and saying it's a reversal of Trump's campaign pledge that he wouldn't interfere with abortion access. 'The Trump administration cannot simply erase four decades of law protecting patients' lives with the stroke of a pen,' Alexa Kolbi-Molinas, deputy director of the ACLU's Reproductive Freedom Project, said in a statement. No matter where a person lives in the United States, Kolbi-Molinas said, they should have access to emergency care, and the ACLU will 'use every lever we have to keep President Trump and his administration from endangering our health and lives.' Fatima Goss Graves, president and CEO of the National Women's Law Center, called the administration hypocritical for its push for a new American 'baby boom' while making a decision that the group says will put people's lives at risk. 'To be clear: this action doesn't change hospitals' legal obligations, but it does add to the fear, confusion, and dangerous delays patients and providers have faced since the fall of Roe v. Wade,' Graves said in a statement.
